Cargando…

Clinical value of fluorine-18α-methyltyrosine PET in patients with gliomas: comparison with fluorine-18 fluorodeoxyglucose PET

BACKGROUND: We investigated the relationship between metabolic activity and histological features of gliomas using fluorine-18α-methyltyrosine ((18)F-FAMT) positron emission tomography (PET) compared with fluorine-18 fluorodeoxyglucose ((18)F-FDG) PET in 38 consecutive glioma patients. The tumor to...

Descripción completa

Detalles Bibliográficos
Autores principales: Horiguchi, Keishi, Tosaka, Masahiko, Higuchi, Tetsuya, Arisaka, Yukiko, Sugawara, Kenichi, Hirato, Junko, Yokoo, Hideaki, Tsushima, Yoshito, Yoshimoto, Yuhei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451375/
https://www.ncbi.nlm.nih.gov/pubmed/28567708
http://dx.doi.org/10.1186/s13550-017-0298-8
_version_ 1783240155507720192
author Horiguchi, Keishi
Tosaka, Masahiko
Higuchi, Tetsuya
Arisaka, Yukiko
Sugawara, Kenichi
Hirato, Junko
Yokoo, Hideaki
Tsushima, Yoshito
Yoshimoto, Yuhei
author_facet Horiguchi, Keishi
Tosaka, Masahiko
Higuchi, Tetsuya
Arisaka, Yukiko
Sugawara, Kenichi
Hirato, Junko
Yokoo, Hideaki
Tsushima, Yoshito
Yoshimoto, Yuhei
author_sort Horiguchi, Keishi
collection PubMed
description BACKGROUND: We investigated the relationship between metabolic activity and histological features of gliomas using fluorine-18α-methyltyrosine ((18)F-FAMT) positron emission tomography (PET) compared with fluorine-18 fluorodeoxyglucose ((18)F-FDG) PET in 38 consecutive glioma patients. The tumor to normal brain ratios (T/N ratios) were calculated, and the relationships between T/N ratio and World Health Organization tumor grade or MIB-1 labeling index were evaluated. The diagnostic values of T/N ratios were assessed using receiver operating characteristic (ROC) curve analyses to differentiate between high-grade gliomas (HGGs) and low-grade gliomas (LGGs). RESULTS: Median T/N ratio of (18)F-FAMT PET was 2.85, 4.65, and 4.09 for grade II, III, and IV gliomas, respectively, with significant differences between HGGs and LGGs (p = 0.006). Both T/N ratio (p = 0.016) and maximum standardized uptake value (p = 0.033) of (18)F-FDG PET showed significant differences between HGGs and LGGs. ROC analysis yielded an optimal cut-off of 3.37 for the T/N ratio of (18)F-FAMT PET to differentiate between HGGs and LGGs (sensitivity 81%, specificity 67%, accuracy 76%, area under the ROC curve 0.776). Positive predictive value was 84%, and negative predictive value was 62%. T/N ratio of (18)F-FAMT PET was not correlated with MIB-1 labeling index in all gliomas, whereas T/N ratio of (18)F-FDG PET was positively correlated (r (s) = 0.400, p = 0.013). Significant positive correlation was observed between T/N ratios of (18)F-FDG and (18)F-FAMT (r (s) = 0.454, p = 0.004), but median T/N ratio of (18)F-FAMT PET was significantly higher than that of (18)F-FDG PET in all grades of glioma. CONCLUSIONS: The T/N ratio of (18)F-FAMT uptake has high positive predictive value for detection of HGGs. (18)F-FAMT PET had higher T/N ratio, with better tumor-normal brain contrast, compared to (18)F-FDG PET in both LGGs and HGGs. Therefore, (18)F-FAMT is a useful radiotracer for the preoperative visualization of gliomas.
format Online
Article
Text
id pubmed-5451375
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-54513752017-06-16 Clinical value of fluorine-18α-methyltyrosine PET in patients with gliomas: comparison with fluorine-18 fluorodeoxyglucose PET Horiguchi, Keishi Tosaka, Masahiko Higuchi, Tetsuya Arisaka, Yukiko Sugawara, Kenichi Hirato, Junko Yokoo, Hideaki Tsushima, Yoshito Yoshimoto, Yuhei EJNMMI Res Original Research BACKGROUND: We investigated the relationship between metabolic activity and histological features of gliomas using fluorine-18α-methyltyrosine ((18)F-FAMT) positron emission tomography (PET) compared with fluorine-18 fluorodeoxyglucose ((18)F-FDG) PET in 38 consecutive glioma patients. The tumor to normal brain ratios (T/N ratios) were calculated, and the relationships between T/N ratio and World Health Organization tumor grade or MIB-1 labeling index were evaluated. The diagnostic values of T/N ratios were assessed using receiver operating characteristic (ROC) curve analyses to differentiate between high-grade gliomas (HGGs) and low-grade gliomas (LGGs). RESULTS: Median T/N ratio of (18)F-FAMT PET was 2.85, 4.65, and 4.09 for grade II, III, and IV gliomas, respectively, with significant differences between HGGs and LGGs (p = 0.006). Both T/N ratio (p = 0.016) and maximum standardized uptake value (p = 0.033) of (18)F-FDG PET showed significant differences between HGGs and LGGs. ROC analysis yielded an optimal cut-off of 3.37 for the T/N ratio of (18)F-FAMT PET to differentiate between HGGs and LGGs (sensitivity 81%, specificity 67%, accuracy 76%, area under the ROC curve 0.776). Positive predictive value was 84%, and negative predictive value was 62%. T/N ratio of (18)F-FAMT PET was not correlated with MIB-1 labeling index in all gliomas, whereas T/N ratio of (18)F-FDG PET was positively correlated (r (s) = 0.400, p = 0.013). Significant positive correlation was observed between T/N ratios of (18)F-FDG and (18)F-FAMT (r (s) = 0.454, p = 0.004), but median T/N ratio of (18)F-FAMT PET was significantly higher than that of (18)F-FDG PET in all grades of glioma. CONCLUSIONS: The T/N ratio of (18)F-FAMT uptake has high positive predictive value for detection of HGGs. (18)F-FAMT PET had higher T/N ratio, with better tumor-normal brain contrast, compared to (18)F-FDG PET in both LGGs and HGGs. Therefore, (18)F-FAMT is a useful radiotracer for the preoperative visualization of gliomas. Springer Berlin Heidelberg 2017-05-31 /pmc/articles/PMC5451375/ /pubmed/28567708 http://dx.doi.org/10.1186/s13550-017-0298-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Horiguchi, Keishi
Tosaka, Masahiko
Higuchi, Tetsuya
Arisaka, Yukiko
Sugawara, Kenichi
Hirato, Junko
Yokoo, Hideaki
Tsushima, Yoshito
Yoshimoto, Yuhei
Clinical value of fluorine-18α-methyltyrosine PET in patients with gliomas: comparison with fluorine-18 fluorodeoxyglucose PET
title Clinical value of fluorine-18α-methyltyrosine PET in patients with gliomas: comparison with fluorine-18 fluorodeoxyglucose PET
title_full Clinical value of fluorine-18α-methyltyrosine PET in patients with gliomas: comparison with fluorine-18 fluorodeoxyglucose PET
title_fullStr Clinical value of fluorine-18α-methyltyrosine PET in patients with gliomas: comparison with fluorine-18 fluorodeoxyglucose PET
title_full_unstemmed Clinical value of fluorine-18α-methyltyrosine PET in patients with gliomas: comparison with fluorine-18 fluorodeoxyglucose PET
title_short Clinical value of fluorine-18α-methyltyrosine PET in patients with gliomas: comparison with fluorine-18 fluorodeoxyglucose PET
title_sort clinical value of fluorine-18α-methyltyrosine pet in patients with gliomas: comparison with fluorine-18 fluorodeoxyglucose pet
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451375/
https://www.ncbi.nlm.nih.gov/pubmed/28567708
http://dx.doi.org/10.1186/s13550-017-0298-8
work_keys_str_mv AT horiguchikeishi clinicalvalueoffluorine18amethyltyrosinepetinpatientswithgliomascomparisonwithfluorine18fluorodeoxyglucosepet
AT tosakamasahiko clinicalvalueoffluorine18amethyltyrosinepetinpatientswithgliomascomparisonwithfluorine18fluorodeoxyglucosepet
AT higuchitetsuya clinicalvalueoffluorine18amethyltyrosinepetinpatientswithgliomascomparisonwithfluorine18fluorodeoxyglucosepet
AT arisakayukiko clinicalvalueoffluorine18amethyltyrosinepetinpatientswithgliomascomparisonwithfluorine18fluorodeoxyglucosepet
AT sugawarakenichi clinicalvalueoffluorine18amethyltyrosinepetinpatientswithgliomascomparisonwithfluorine18fluorodeoxyglucosepet
AT hiratojunko clinicalvalueoffluorine18amethyltyrosinepetinpatientswithgliomascomparisonwithfluorine18fluorodeoxyglucosepet
AT yokoohideaki clinicalvalueoffluorine18amethyltyrosinepetinpatientswithgliomascomparisonwithfluorine18fluorodeoxyglucosepet
AT tsushimayoshito clinicalvalueoffluorine18amethyltyrosinepetinpatientswithgliomascomparisonwithfluorine18fluorodeoxyglucosepet
AT yoshimotoyuhei clinicalvalueoffluorine18amethyltyrosinepetinpatientswithgliomascomparisonwithfluorine18fluorodeoxyglucosepet